JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

Search

Cencora Inc

Atvērts

SektorsVeselības aprūpe

305.12 -2.14

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

298.7

Max

312.67

Galvenie mērījumi

By Trading Economics

Ienākumi

906M

566M

Pārdošana

2.2B

86B

P/E

Sektora vidējais

37.19

67.147

EPS

4.08

Dividenžu ienesīgums

0.73

Peļņas marža

0.659

Darbinieki

47,000

EBITDA

858M

1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+29.04% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.73%

2.36%

Nākamie ieņēmumi

2026. g. 6. maijs

Nākamais dividenžu datums

2026. g. 1. jūn.

Nākamais Ex dividenžu datums

2026. g. 15. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-10B

60B

Iepriekšējā atvēršanas cena

307.26

Iepriekšējā slēgšanas cena

305.12

Ziņu noskaņojums

By Acuity

7%

93%

6 / 348 Rangs Healthcare

Cencora Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. apr. 23:53 UTC

Peļņas

Naver Posts Weaker First-Quarter Earnings

2026. g. 29. apr. 23:41 UTC

Karstas akcijas

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026. g. 29. apr. 23:55 UTC

Peļņas

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 29. apr. 23:54 UTC

Peļņas

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026. g. 29. apr. 23:52 UTC

Peļņas

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026. g. 29. apr. 23:51 UTC

Peļņas

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026. g. 29. apr. 23:51 UTC

Tirgus saruna

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026. g. 29. apr. 23:34 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026. g. 29. apr. 23:22 UTC

Peļņas

China Longyuan 1Q Net CNY1.70B, Down 14%

2026. g. 29. apr. 23:22 UTC

Peļņas

China Longyuan: Power Generation Down 2.9% as of End-March

2026. g. 29. apr. 23:20 UTC

Peļņas

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026. g. 29. apr. 23:20 UTC

Peļņas

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Loss Narrows>000002.SZ

2026. g. 29. apr. 23:18 UTC

Peļņas

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026. g. 29. apr. 23:17 UTC

Peļņas

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026. g. 29. apr. 23:15 UTC

Peļņas

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026. g. 29. apr. 23:15 UTC

Peļņas

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026. g. 29. apr. 23:13 UTC

Peļņas

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026. g. 29. apr. 23:12 UTC

Peļņas

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026. g. 29. apr. 23:11 UTC

Peļņas

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026. g. 29. apr. 23:11 UTC

Peļņas

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026. g. 29. apr. 23:04 UTC

Peļņas

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026. g. 29. apr. 23:04 UTC

Peļņas

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Salīdzinājums

Cenas izmaiņa

Cencora Inc Prognoze

Cenas mērķis

By TipRanks

29.04% augšup

Prognoze 12 mēnešiem

Vidējais 401.86 USD  29.04%

Augstākais 429 USD

Zemākais 360 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cencora Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

6

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

6 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat